← Back to Search

Sequence 2 (BCADHEGF) for Healthy Subjects

N/A
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up needle insertion to 240 minutes
Awards & highlights

Summary

The goal of this exploratory study is to learn about the effects of subcutaneous injections on healthy participants. The study aims to explore how different delivery methods containing a solution impacts injection pain, without an active drug to complicate the results. Pain assessments will be performed visually and at the injection site to determine the level of pain experienced after each injection. This study will last approximately 40 days, including screening, assessment, and follow-up.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~needle insertion to 240 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and needle insertion to 240 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual analogue scale (VAS) Pain score at Injection Site

Trial Design

8Treatment groups
Experimental Treatment
Group I: Sequence 8 (HAGBFCED)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group II: Sequence 7 (GHFAEBDC)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group III: Sequence 6 (FGEHDACB)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group IV: Sequence 5 (EFDGCHBA)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group V: Sequence 4 (DECFBGAH)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group VI: Sequence 3 (CDBEAFHG)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group VII: Sequence 2 (BCADHEGF)Experimental Treatment1 Intervention
Syringe pump is used to SC administer buffer solution with hyaluronic acid as a viscosity agent
Group VIII: Sequence 1 (ABHCGDFE)Experimental Treatment1 Intervention
Syringe pump is used to subcutaneously (SC) administer buffer solution with hyaluronic acid as a viscosity agent

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,221,791 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,358 Previous Clinical Trials
418,237 Total Patients Enrolled
~21 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top